Detalles de la búsqueda
1.
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
N Engl J Med
; 386(9): 837-846, 2022 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35235726
2.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1885-1898, 2021 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33725432
3.
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
N Engl J Med
; 385(25): 2348-2360, 2021 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34587382
4.
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
N Engl J Med
; 383(5): 415-425, 2020 07 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-32726528
5.
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
N Engl J Med
; 388(16): 1533-1534, 2023 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018470
6.
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
N Engl J Med
; 386(9): 892-894, 2022 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35235733
7.
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
J Infect Dis
; 216(11): 1362-1370, 2017 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29029260
8.
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
Antimicrob Agents Chemother
; 61(3)2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27956428
9.
Recruitment and retention of pregnant women into clinical research trials: an overview of challenges, facilitators, and best practices.
Clin Infect Dis
; 59 Suppl 7: S400-7, 2014 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25425718
10.
Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine.
J Immunol
; 188(10): 5054-62, 2012 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22504653
11.
Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants.
J Clin Pharmacol
; 64(5): 555-567, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38294353
12.
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
J Pediatric Infect Dis Soc
; 13(2): 144-147, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38219024
13.
Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region.
Malar J
; 12: 11, 2013 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-23297680
14.
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
Nat Med
; 29(5): 1172-1179, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37095249
15.
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
J Pediatric Infect Dis Soc
; 12(8): 477-480, 2023 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37466917
16.
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Lancet Child Adolesc Health
; 7(3): 180-189, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36634694
17.
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Lancet Microbe
; 4(11): e863-e874, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37783221
18.
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.
Nat Commun
; 14(1): 4347, 2023 07 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37468530
19.
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Vaccine
; 41(23): 3486-3492, 2023 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37149443
20.
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine.
NPJ Vaccines
; 8(1): 36, 2023 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36899062